Dacinostat

Cat. No.：404951-53-7

CAS No. ：404951-53-7

规格

价格(RMB)

库存
5mg

￥1283

In-stock
10mg

￥2052

In-stock
50mg

￥5472

In-stock
100mg

￥5472

Inquiry
200mg

￥5472

Inquiry

查看相关靶点产品

产品资料
参考文献

产品名称:	Dacinostat
CAS No.:	404951-53-7
Chemical Name:
Synonyms:	NVP-LAQ824; LAQ824
分子量:	379.45
分子式:	C₂₂H₂₅N₃O₃
SMILES:	O=C(NO)/C=C/C1=CC=C(CN(CCO)CCC2=CNC3=C2C=CC=C3)C=C1
存储:	Please store the product under the recommended conditions in theCertificate of Analysis.
运输:	Room temperature in continental US; may vary elsewhere.

Select Batch:

Purity: 0.98

Catley, L., Weisberg, E., Tai, Y.T., et al.NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myelomaBlood102(7),2615-2622(2003)', 'Dokmanovic, M., Clarke, C., and Marks, P.A.Histone deacetylase inhibitors: Overview and perspectivesMol. Cancer Res.5(10),981-989(2007)', 'Zheng, Y.G., Wu, J., Chen, Z., et al.Chemical regulation of epigenetic modifications: Opportunities for new cancer therapyMed. Res. Rev.28(5),645-687(2008)', 'Rosato, R.R., Almenara, J.A., Maggio, S.C., et al.Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactionsMol. Cancer Ther.7(10),3285-3297(2008)', 'Nimmanapalli, R., Fuino, L., Bali, P., et al.Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cellsCancer Res.63(16),5126-5135(2003)', 'Fiskus, W., Ren, Y., Mohapatra, A., et al.Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-α levels and transcriptional activity: A result of hyperacetylation and inhibition of chaperone function of heat shock protein 90Clin. Cancer Res.13(16),4882-4890(2007)', 'de Bono, J.S., Kristeleit, R., Tolcher, A., et al.Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumorsClin. Cancer Res.14(20),6663-6673(2008)